高橋晴美 (Harumi Takahashi) - マイポータル - researchmap

基本情報

所属: 明治薬科大学薬学部薬剤学科薬物治療学教室講師,助教授

学位: 博士(薬学)

J-GLOBAL ID: 200901078185705320
researchmap会員ID: 1000196104

研究キーワード

2

研究分野

1

ライフサイエンス / 薬理学 /

受賞

1

1999年

臨床薬理研究振興財団学術論文賞

MISC

30

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

H Takahashi, H Echizen

PHARMACOGENOMICS JOURNAL 3(4) 202-214 2003年
Population difference in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese

Clin. Pharmacol. Ther. 73, 253-263 2003年
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

H Takahashi, H Echizen

PHARMACOGENOMICS JOURNAL 3(4) 202-214 2003年
Population difference in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese

Clin. Pharmacol. Ther. 73, 253-263 2003年
Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children

Int.J.Clin.Pharmacol.ther 40(1) 485-492 2002年
Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children

Int.J.Clin.Pharmacol.ther 40(1) 485-492 2002年
Pharmacogenetics of warfarin elimination and its clinical implications

Clin.Pharmacokinet 401, 587-603 2001年
Pharmacogenetics of warfarin elimination and its clinical implications

Clin.Pharmacokinet 401, 587-603 2001年
Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

Clin. Pharmacol. Ther. 68(5) 541-555 2000年
Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: Application of in vitro approaches to predicting in vivo reduction of (S)-warfarin clearance

H Takahashi, T Kashima, S Kimura, N Murata, T Takaba, K Iwade, T Abe, H Tainaka, T Yasumori, H Echizen

DRUG METABOLISM AND DISPOSITION 27(10) 1179-1186 1999年10月
Potentiation of anticoagulant effect of warfarin causecl by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.

Clinical Pharmacology and Therapeutics 66(6) 569-581 1999年
Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu(359) variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

H Takahashi, T Kashima, S Nomoto, K Iwade, H Tainaka, T Shimizu, Y Nomizo, N Muramoto, S Kimura, H Echizen

PHARMACOGENETICS 8(5) 365-373 1998年10月
新しい血清遊離形ワルファリン光学異性体濃度測定法による同薬の血清濃度・抗凝固効果関係の検討

中畑宙巳, 高橋晴美, 越前宏俊, 緒方宏泰, 力久忠昭, 久保鈴子, 村越功治, 太田仁, 石井漱一, 名越秀樹 …

病院薬学 24(2) 123-129 1998年
Metabolism of Warfarin Enantiomers in Japanese Patients with Heart Disease Having Different CYP2C9 and CYP2C19 Genotypes

Clin. Pharmacol. Ther. 63(5) 519-528 1998年
Characterization of the hepatic canalicular membrane transport of a model oligopeptide: Ditekiren

H Takahashi, RB Kim, PR Perry, GR Wilkinson

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 281(1) 297-303 1997年4月
Determination of Unbound Warfarin Enantiomers in Human Plasma and 7-Hydroxywarfarin in Human Urine by Chiral Stationary-phase Liquid Chromatography with Ultraviolet or Fluorescence and On-line Circular Dichroism Detection

J. Chromatogr. B 701(1) 71-80 1997年
P-glycoprotein-mediated transport of an oligopeptide, ditekiren, across the rat hepatic canalicular membrane.

FASEB J. 9,A308 1995年
Variability in absorption lag time of periodical phosphate under fasting and pre- and post-meal conditions.

Biopharm. Drug Dispos. 15(6) 505-517 1994年
Dosing rate-dependent relationship between prolranolol plasma concentration and β-blockade.

J. Pharmacol. Exp. Ther. 265 681 1993年
Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.

Biopharm. Drug Dispos. 14(5) 409-418 1993年

もっとみる

所属学協会

3

共同研究・競争的資金等の研究課題

2